Frequently Asked Questions
Clinical studies are important to understand more about whether a potential treatment may be effective. Clinical studies also help us learn more about the side effects of a potential treatment. Thousands of people all around the world take part in clinical studies every year.
Yes, taking part in any clinical study is completely voluntary. If you decide to stop taking part at any time, it will not affect your future medical care in any way.
Before you can join any clinical study, you need to agree to join by giving your consent. You must fully understand what will happen in the clinical study before you agree to participate. This is called being ‘informed’. You should not feel any pressure to give your consent. Feel free to discuss the clinical study with family and friends before you make your decision.
The investigational drug in this study is being tested to see if it can reduce hallucinations and delusions in people with Alzheimer's disease. The investigational drug is thought to regulate parts of the brain involved in hallucinations and delusions (psychosis)1.
In this clinical study we are comparing an investigational drug with a placebo. The placebo looks identical to the investigational drug, but does not contain the active ingredient.
- Yohn et al. 2022. Trends Pharmacol Sci. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
You will receive the study drug (the investigational drug or placebo) from the study team. The study drug will be provided as tablets to be taken by mouth twice daily.
You would need to make approximately 7 visits to your chosen study site over a period of around 13 weeks.
There are some risks associated with taking any medicine, and the investigational drug in the VISTA clinical study is no different. You may experience side effects, or find that your symptoms do not improve or get worse. It is important that you tell your study doctor if you are worried about anything or if anything about your health changes.
Participants who complete this study may have the option to enroll in a year-long extension study, if one is available and they are eligible. All participants in the extension will receive the investigational drug (there will be no placebo group).
If you do not complete the study or do not choose to continue in the extension, you will no longer receive the study drug after your participation has ended, even if you found it beneficial, unless otherwise required pursuant to applicable law. For any medical care, you can contact your usual treating physician, as you did before the study.
All of the data collected from each participant is pseudonymized (identifying details are hidden) and then analyzed by a team of scientists, who then produce a report with the findings for the professional bodies that oversee the development of investigational drugs. You cannot be identified in this report and your name will not appear in any results published.
You are free to leave the study at any time without giving a reason. It will not affect your regular medical care.
Information about your personal health will be kept private. If you decide to contact us, your details will be transferred to the study team at the site you’ve chosen. Someone from the study team will contact you to better understand if the study is right for you. Your personal information will not be revealed to anyone outside of the study team without your consent, unless required by law or regulations of the local regulatory agency in your country.